Jaguar Health to Hold Virtual Conference Call on OnTarget Phase 3 Trial Results

Summary

Jaguar Health, Inc. (NASDAQ: JAGX) will hold a virtual fireside chat on June 10, 2025, at 9 AM ET as part of the Lytham Partners Spring 2025 Focus Series. CEO Lisa Conte will discuss the company’s upcoming meeting with the FDA concerning the third phase OnTarget trial results for breast cancer patients. Jaguar plans to pursue expanded use programs for patients who do not meet key trial criteria.

Impact Analysis

The event primarily reflects a regulatory event focusing on the FDA’s assessment of crofelemer’s third-phase trial results, which showed statistical significance for a subset of breast cancer patients. This aligns with Jaguar Health’s broader strategy of advancing crofelemer’s use for cancer-related treatments, marking a significant product milestone. The first-order effects include potential regulatory approval, which could expand market access and revenue prospects, improving investor confidence. Risks involve regulatory hurdles and the need for additional data to support broader applications, creating potential setbacks.Reuters+ 2